 Connection
Peter Gottlieb to Prognosis
This is a "connection" page, showing publications Peter Gottlieb has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.078 |
|
|
|
-
Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021 08; 9(8):502-514.
Score: 0.025
-
Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC. Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia. 2020 04; 63(4):885-886.
Score: 0.023
-
Bellin MD, Moran A, Wilhelm JJ, O'Brien TD, Gottlieb PA, Yu L, Dunn TB. Development of Autoimmune-Mediated ? Cell Failure After Total Pancreatectomy With Autologous Islet Transplantation. Am J Transplant. 2015 Jul; 15(7):1991-4.
Score: 0.016
-
Baker PR, Nanduri P, Gottlieb PA, Yu L, Klingensmith GJ, Eisenbarth GS, Barker JM. Predicting the onset of Addison's disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin Endocrinol (Oxf). 2012 May; 76(5):617-24.
Score: 0.013
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|